help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oppizzi, G.
Right arrow Articles by Liuzzi, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oppizzi, G.
Right arrow Articles by Liuzzi, A.

Journal of Clinical Endocrinology & Metabolism, Vol 63, 1348-1353, Copyright © 1986 by Endocrine Society

ARTICLES

Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation

G Oppizzi, MM Petroncini, D Dallabonzana, R Cozzi, G Verde, PG Chiodini and A Liuzzi

The relationship between basal and stimulated plasma GH and somatomedin- C (SmC) levels in acromegalic patients was evaluated. The basal plasma SmC levels of 66 patients were significantly correlated (P less than 0.01) with mean daily plasma GH levels, but not with the percent GH increase after GH-releasing hormone or TRH or the GH decrease after acute bromocriptine administration. Bromocriptine (7.5-15 mg/day) administration for 9.2 +/- 0.9 (+/- SD) months in 20 patients significantly (P less than 0.05) decreased GH levels. SmC decreased significantly [from 9.8 +/- 1.9 to 5.1 +/- 0.7 U/ml (mean +/- SE)] only in the 10 patients who had the more marked GH inhibition. The administration of a somatostatin analog, SMS 201-995 (100 micrograms twice daily), to 12 patients for 16 weeks significantly decreased plasma GH and SmC levels beginning on the second day of therapy; normal SmC levels were achieved in 5 of 12 patients. Pituitary adenomectomy resulted in normal GH and SmC levels in 10 of 12 and 8 of 12 patients, respectively. Our data indicate an overall dependency of plasma SmC levels on plasma GH levels in acromegaly, although similar GH levels may have differing somatomedin-stimulating activities. A derangement in the feedback mechanisms controlling GH secretion is indicated by the failure of elevated SmC levels to influence the GH responsiveness to releasing hormones. In evaluating pharmacological or surgical treatments of acromegaly, a single plasma SmC value can reliably replace several plasma GH determinations.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
S. Jehle, C. M. Reyes, R. E. Sundeen, and P. U. Freda
Alternate-Day Administration of Pegvisomant Maintains Normal Serum Insulin-Like Growth Factor-I Levels in Patients with Acromegaly
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1588 - 1593.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. U. Freda, K. D. Post, J. S. Powell, and S. L. Wardlaw
Evaluation of Disease Status with Sensitive Measures of Growth Hormone Secretion in 60 Postoperative Patients with Acromegaly
J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 3808 - 3816.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1986 by The Endocrine Society